E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.
about
FXR regulates liver repair after CCl4-induced toxic injuryOIP5, a target of miR-15b-5p, regulates hepatocellular carcinoma growth and metastasis through the AKT/mTORC1 and β-catenin signaling pathways.c-MYC-Making Liver Sick: Role of c-MYC in Hepatic Cell Function, Homeostasis and Disease.Acquired activation of the Akt/cyclooxygenase-2/Mcl-1 pathway renders lung cancer cells resistant to apoptosisE2F1 regulates cellular growth by mTORC1 signaling.Development of mouse hepatocyte lines permissive for hepatitis C virus (HCV)Dissecting the expression of EEF1A1/2 genes in human prostate cancer cells: the potential of EEF1A2 as a hallmark for prostate transformation and progressionSpherical cell shape of FLC-4 cell, a human hepatoma cell, enhances hepatocyte-specific function and suppresses tumor phenotype through the integration of mRNA-microRNA interactionMYC activates stem-like cell potential in hepatocarcinoma by a p53-dependent mechanism.Targeting the PI3K/Akt/mTOR pathway in hepatocellular carcinoma.Increased lipogenesis, induced by AKT-mTORC1-RPS6 signaling, promotes development of human hepatocellular carcinoma.miRNA-205 suppresses melanoma cell proliferation and induces senescence via regulation of E2F1 protein.mTORC2 promotes cell survival through c-Myc-dependent up-regulation of E2F1.POH1 deubiquitylates and stabilizes E2F1 to promote tumour formation.Upregulation of the PI3K/Akt pathway in the tumorigenesis of canine thyroid carcinomamTOR inhibitors synergize on regression, reversal of gene expression, and autophagy in hepatocellular carcinoma.Decreased MicroRNA-26a expression causes cisplatin resistance in human non-small cell lung cancer.Intestine-specific homeobox (ISX) upregulates E2F1 expression and related oncogenic activities in HCC.Apoptosis and autophagy: Targeting autophagy signalling in cancer cells -'trick or treats'?An overview of stress response and hypometabolic strategies in Caenorhabditis elegans: conserved and contrasting signals with the mammalian system.MiR-15a suppresses hepatocarcinoma cell migration and invasion by directly targeting cMyb.In silico and experimental analyses predict the therapeutic value of an EZH2 inhibitor GSK343 against hepatocellular carcinoma through the induction of metallothionein genes.E2F1: a promising regulator in ovarian carcinoma.V-ATPase: a master effector of E2F1-mediated lysosomal trafficking, mTORC1 activation and autophagyRapamycin combined with celecoxib enhanced antitumor effects of mono treatment on chronic myelogenous leukemia cells through downregulating mTOR pathway.Small compound bigelovin exerts inhibitory effects and triggers proteolysis of E2F1 in multiple myeloma cells.MiR-449c targets c-Myc and inhibits NSCLC cell progression.HBV core promoter mutations promote cellular proliferation through E2F1-mediated upregulation of S-phase kinase-associated protein 2 transcription.Mammalian target of rapamycin regulates isoliquiritigenin-induced autophagic and apoptotic cell death in adenoid cystic carcinoma cells.Strain-dependent viral dynamics and virus-cell interactions in a novel in vitro system supporting the life cycle of blood-borne hepatitis C virus.Tankyrase inhibitors suppress hepatocellular carcinoma cell growth via modulating the Hippo cascade.PCI-24781 down-regulates EZH2 expression and then promotes glioma apoptosis by suppressing the PIK3K/Akt/mTOR pathway.Functional crosstalk between AKT/mTOR and Ras/MAPK pathways in hepatocarcinogenesis: implications for the treatment of human liver cancer.Cell therapy from bench to bedside: Hepatocytes from fibroblasts - the truth and myth of transdifferentiation.E2F transcription factors and digestive system malignancies: how much do we know?Cigarette smoking exacerbates nonalcoholic fatty liver disease in obese rats.Dysregulation of apoptosis in hepatocellular carcinoma cells.E2F-1 is overexpressed and pro-apoptotic in human hepatocellular carcinoma.Human O6 -methylguanine-DNA methyltransferase containing C145A does not prevent hepatocellular carcinoma in C3HeB/FeJ transgenic mice.Distinct microRNA profiles are associated with the severity of hepatitis C virus recurrence and acute cellular rejection after liver transplantation.
P2860
Q28396872-51DB61B8-4D9D-4B7B-BD28-C895BB21E228Q33566841-FB4E7742-D170-4FEB-9B77-0E5D5DEB5B37Q33608524-75C44580-FBAA-4284-872D-AAF3D7EAFFE0Q33714703-36846952-02BA-47C2-98DE-9A1C7CB6B482Q33808832-9A52D775-0344-4748-B029-DAD156E004BCQ33952278-B8EB5C4A-36E4-4A1E-9FAD-3090D9B98C97Q34077384-123025DE-A12A-4965-AE31-9CEB423531D6Q34315717-835874F7-E085-49AB-AEBF-614A3FFC4E0FQ34353174-721170C3-AE4C-43F0-9DFA-747EECA8530EQ34632966-FA7721CA-64F1-47E5-B1CE-F68AAC33A637Q34672477-42A7255C-8154-438C-B45E-7908CEABCBF4Q34947386-BD719CE0-738D-4841-B5FE-09E118AA1CAEQ36149386-075553A8-BCF8-48D3-9E6D-0E049E5195B3Q36839501-4C13E73E-2CD6-4A98-B7CE-E4EEE66A9673Q36975457-0BE6D4E1-BC79-46FB-8088-8E5F76B8A4F8Q36987718-CC41211B-5B5C-475A-9583-96B1B9773D1BQ37013250-D8DDE699-2D3F-4761-956E-438A88C20477Q37392876-5EE399D2-9359-4834-AE33-A0014066081CQ37605154-0E7BA059-5ABF-4A3E-9E0A-87704C388614Q37678202-DE017468-DF5D-4899-9FBE-D23997F17F1BQ37685247-15297A93-99A5-443E-AB4B-26AF0636FA1CQ38388649-83167590-E5F8-4D1B-B35C-387795295416Q38691452-D6A0D42E-C91B-495E-A7E2-A3E97EFFB117Q38836359-4A92DFFF-1B91-4597-AECA-095BE624CB1BQ39010100-8FF20937-BF71-4592-B4C4-1E2E65EC37E9Q39080639-06ED8B76-D6FD-422F-8A1E-40CA46F701A4Q39178996-2557DBC3-6F00-4542-9A67-7AADD41F7830Q39205216-6A5C724C-A978-4E7F-B29C-F56086642C4EQ39466267-3096EC4A-3F1C-4257-B077-8A7C0BCC0A7DQ39844023-D273CEE8-EA99-4A48-A35A-1A9E112BF9A3Q41634975-851D11D0-C681-4641-AC0D-492693F08658Q41692030-C943CBB9-BCEA-455F-9038-69409282AE93Q41832567-C6ADD26B-BD4B-4826-BB84-14DB811485ABQ42610267-F6C1D78B-DAEF-4556-83B4-C7C36B97B04AQ42772377-5B7BAE86-626B-4D39-A31D-DDB028F4DE94Q43078753-B833D9E8-328D-4662-9405-DB524D015A9FQ43166036-DC92671A-3565-4E18-A673-BA922084E195Q43537069-C07E8EDF-2DC9-4A02-8BBD-F88C10CD1767Q43872952-1B2AABF4-927D-4E2D-BC84-A0E4B1664F02Q45352623-3A1C1321-5E38-48C6-BB92-BEB349E68562
P2860
E2F1 inhibits c-Myc-driven apoptosis via PIK3CA/Akt/mTOR and COX-2 in a mouse model of human liver cancer.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 17 July 2008
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
E2F1 inhibits c-Myc-driven apo ...... e model of human liver cancer.
@en
E2F1 inhibits c-Myc-driven apo ...... e model of human liver cancer.
@nl
type
label
E2F1 inhibits c-Myc-driven apo ...... e model of human liver cancer.
@en
E2F1 inhibits c-Myc-driven apo ...... e model of human liver cancer.
@nl
prefLabel
E2F1 inhibits c-Myc-driven apo ...... e model of human liver cancer.
@en
E2F1 inhibits c-Myc-driven apo ...... e model of human liver cancer.
@nl
P2093
P2860
P1433
P1476
E2F1 inhibits c-Myc-driven apo ...... e model of human liver cancer.
@en
P2093
Diego F Calvisi
Elizabeth A Conner
Miriam Farina
Snorri S Thorgeirsson
Valentina M Factor
P2860
P304
P356
10.1053/J.GASTRO.2008.07.012
P407
P577
2008-07-17T00:00:00Z